Majdi Halabi

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Iacopo Olivotto, Artur Oręziak, Roberto Barriales‐Villa et al. · The Lancet · 2020 · 1.1K citations · Full text

Cardiomyopathy, Structural Heart Disease, Cardiovascular Disease +2

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

Stuart J. Connolly, John W. Eikelboom, Jackie Bosch et al. · The Lancet · 2017 · 749 citations · Full text

Thrombosis, Cardiovascular Disease, Atherosclerosis +12

Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

Piotr Ponikowski, Bridget‐Anne Kirwan, Stefan D. Anker et al. · The Lancet · 2020 · 723 citations · Full text

Heart Failure, Iron Metabolism, Clinical Nutrition +5

Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial

Jozef Bartúnek, André Terzic, Beth A. Davison et al. · European Heart Journal · 2016 · 180 citations · Full text

Real-time MRI-guided right heart catheterization in adults using passive catheters

Kanishka Ratnayaka, Anthony Z. Faranesh, Michael S. Hansen et al. · European Heart Journal · 2012 · 100 citations · Full text